Skip to main content
. Author manuscript; available in PMC: 2011 Feb 21.
Published in final edited form as: Lancet Oncol. 2009 Oct 21;11(1):29–37. doi: 10.1016/S1470-2045(09)70284-0

Table 5.

Reason for discontinuation

High dose
(n=223)
Low dose
(n=222)
Total
(n=445)
Treatment completed per protocol 52(25) 49(25) 101(25)
Disease progression 33(16) 35(18) 68(17)
Adverse events or complications 56(27) 37(19) 93(23)
Death on study 8(4) 5(3) 13(3)
Patient withdrawal or refusal 11(5) 10(5) 21(5)
Alternative therapy 30(14) 40(21) 70(17)
Other complicating disease 2(1) 1(<1) 3(1)
Other 17(8) 16(8) 33(8)

Data are number (%).